About Us

Proniras Corporation (“Proniras”) is a clinical-stage biotechnology company focused on the development of novel small-molecule therapeutics for the treatment of substance use and specialty central nervous system (CNS) disorders.  The Company’s lead program is tezampanel, (PRN-001-01), a novel modulator of glutaminergic signaling designed to treat patients seeking to recover from opioid addiction and associated conditions.  Tezampanel reduces brain over-activation in circuits involved in drug withdrawal, addiction, and mental illness without relying on direct stimulation or antagonism of the opioid system.  Tezampanel has the potential to provide significant improvement in the treatment of opiate withdrawal syndrome, opioid overdoses, and conversion to long term medications that can help patients addicted to opiates to achieve full remission from their illness.